The size of the sample was estimated considering a crossover, clinical trial design and following the proposal by Hills and Armitage accepting a type I error of 0.05, a power of 90%, and assuming a difference of 20% in the HOMA index after 6 months of treatment with candesartan (3 to 2.4) and a maximum standard deviation of 1.5, sample size of 84 subjects was estimated. By adjusting the rate of losses of 8%, the final sample size is 100 subjects (50 in each group).